Relevance of the assessment of natriuretic peptide plasma concentrations in hypertensive pregnant women

Gondek, Agata; Jagodzińska, Aleksandra; Pietrzak, Bronisława; Mamcarz, Artur; Cudnoch-Jędrzejewska, Agnieszka

doi:10.1080/1354750x.2020.1795264

Cited by 4 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with a prior medical history of preeclampsia should be followed closely throughout pregnancy. Of note, an increase in BNP can precede the development of preeclampsia, as described above, and serial TTE and natriuretic peptide follow-up throughout pregnancy should be considered in high-risk patients ( 18 ). Interdisciplinary management of these patients in a cardio-obstetric clinic is highly recommended, and high-risk patients should be referred to centers offering such services.…”

Section: Discussionmentioning

confidence: 99%

Natriuretic peptide biomarkers in the imminent development of preeclampsia

Marek-Iannucci¹,

Oliveros²,

Brailovsky³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Preeclampsia is the most common cause of morbidity and mortality in pregnancy, the incidence being significantly higher in low-income countries with reduced access to health care. Women with preeclampsia are at a higher risk of developing cardiovascular disease with a poorer long-term outcome. Early recognition and treatment are key to improving short- and long-term outcomes. Approximately 3%–5% of pregnant women will develop preeclampsia, with potentially fatal outcomes. Despite ongoing research, the exact pathophysiologic mechanism behind its development remains unclear. In this brief report, we describe the potential role of natriuretic peptides as biomarkers in the imminent development of preeclampsia. In a retrospective manner, we analyzed changes in the left ventricular ejection fraction and left atrial volume and increases in natriuretic peptide in correlation with the development of preeclampsia. We found that three out of four patients developed a significant increase in natriuretic peptide, which correlated with the development of preeclampsia and/or peripartum cardiomyopathy. Significant increases in natriuretic peptides around the time of delivery might be a marker for the imminent development of preeclampsia. Close monitoring of natriuretic peptide levels in the peripartum period could give important insight into the imminent development of preeclampsia in high-risk patients. Close follow-up in specialized cardio-obstetric clinics is highly recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Natriuretic peptide biomarkers in the imminent development of preeclampsia

Marek-Iannucci¹,

Oliveros²,

Brailovsky³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Natriuretic peptides, including atrial, B-type, and C-type natriuretic peptides, are a group of polypeptides with a wide range of physiological effects, including the promotion of natriuresis and diuresis, vasodilation, RAAS inhibition, reduction of sympathetic nerve activity, and the suppression of proliferation and fibrosis ( 21 ). Sacubitril/valsartan, a compound with a co-crystal structure composed of the neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan, is the first dual angiotensin receptor and neprilysin inhibitor ( 22 , 23 ).…”

Section: Introductionmentioning

confidence: 99%

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus

Gan

Lyu²,

Yang³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a global public health problem, and cardiovascular disease is the most common cause of death in patients with CKD. The incidence and prevalence of cardiovascular events during the early stages of CKD increases significantly with a decline in renal function. More than 50% of dialysis patients die from cardiovascular disease, including coronary heart disease, heart failure, arrhythmia, and sudden cardiac death. Therefore, developing effective methods to control risk factors and improve prognosis is the primary focus during the diagnosis and treatment of CKD. For example, the SPRINT study demonstrated that CKD drugs are effective in reducing cardiovascular and cerebrovascular events by controlling blood pressure. Uncontrolled blood pressure not only increases the risk of these events but also accelerates the progression of CKD. A co-crystal complex of sacubitril, which is a neprilysin inhibitor, and valsartan, which is an angiotensin receptor blockade, has the potential to be widely used against CKD. Sacubitril inhibits neprilysin, which further reduces the degradation of natriuretic peptides and enhances the beneficial effects of the natriuretic peptide system. In contrast, valsartan alone can block the angiotensin II-1 (AT1) receptor and therefore inhibit the renin–angiotensin–aldosterone system. These two components can act synergistically to relax blood vessels, prevent and reverse cardiovascular remodeling, and promote natriuresis. Recent studies have repeatedly confirmed that the first and so far the only angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan can reduce blood pressure more effectively than renin–angiotensin system inhibitors and improve the prognosis of heart failure in patients with CKD. Here, we propose clinical recommendations based on an expert consensus to guide ARNI-based therapeutics and reduce the occurrence of cardiovascular events in patients with CKD.

show abstract

“…This type occurs in about 90-95% of people with diabetes, which was previously called non-insulin-dependent diabetes or adult diabetes [2]. Hence, diabetes II affects people in the later stages of their lives and occurs in younger age when it is genetic, since the genes play a role in the occurrence of diabetes II [3]. There are several factors that affect the complications of diabetes, namely gender, age, educational status, marital status, income, drinking alcohol, diet, cardiac activity, family history of diabetes, duration of diabetes, preventive care services, body mass index (BMI) and blood pressure [4].…”

Section: Introductionmentioning

confidence: 99%

Assessing the Level of a Trial Natriuretic Peptide and Some Biochemical Parameters in Men With Type 2 Diabetic Nephropathy

AL-FATLAWI¹,

Jwad²

2022

UPJOZ

View full text Add to dashboard Cite

The Aim: The current study is conducted to diagnose the relationship between ANP levels and diabetic nephropathy, the applicability of adopting it as a biomarker or an early index to prevent renal failure. Study Design: The current study estimates the levels of atrial natriuretic peptide and some biochemical parameters in healthy subjects and patients with type 2 diabetes. Place and Duration of Study: The study duration was from 1/3/2021 to 1/10/2021. The patients were divided into several groups based on their age, diabetic duration, albumin to creatinine ratio (ACR) and glomerular filtration rate. Methodology: It determines the possibility of adopting these levels in diagnosing the progression of diabetic nephropathy. The study also included a follow-up of (60) men with type 2 diabetes who were attending the Diabetes and Endocrinology Center of Al-Sadr Medical Hospital in Najaf, as well as (15) men from the Dialysis Center of the same hospital, and (15) healthy men as a control group, their ages were (30-80) years. Results: The trial showed a significant effect (P<0.05) for age groups and diabetic duration on the levels of atrial natriuretic peptide, cystatin C, amyloid A, serum creatinine, albumin to creatinine ratio in urine, and glomerular filtration rate. However, no significant differences (P>0.05) were observed in the albumin level in serum. Moreover, the results showed a noticeable increase (P<0.05) in the levels of atrial natriuretic peptide, cystatin C, amyloid A, creatinine in serum and glomerular filtration rate with an increase in albuminuria. Conclusion: A significant increment was indicated by the results reading (P<0.05) in the levels of atrial natriuretic peptide, cystatin C, amyloid A, creatinine in serum and the ratio of albumin to creatinine with the progression of the stages of diabetic nephropathy.

show abstract

Relevance of the assessment of natriuretic peptide plasma concentrations in hypertensive pregnant women

Cited by 4 publications

References 81 publications

Natriuretic peptide biomarkers in the imminent development of preeclampsia

Natriuretic peptide biomarkers in the imminent development of preeclampsia

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus

Assessing the Level of a Trial Natriuretic Peptide and Some Biochemical Parameters in Men With Type 2 Diabetic Nephropathy

Contact Info

Product

Resources

About